.jetcityimage/iStock Editorial by means of Getty Images Morgan Stanley has picked Eli Lilly (NYSE: LLY) as its best biopharma choice for 2025 and rated yet another nine titles in the space as obese. The investment financial institution pointed out in a note that it continues to believe “diabesity is actually readied to become.